EGFR and non-small cell lung carcinoma: Combined EGFR TKI and Akt inhibitor treatment of the EGFR-TKI-resistant NSCLC cells generally induced a complete inhibition of phosphorylation of the two downstream targets PRAS40 and FOXO1/3A.